About the GSCID
The JCVI Genomic Sequencing Center for Infectious Diseases (GSCID), sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), addresses the scientific community's need for additional sequencing and genotyping of microorganisms and invertebrate vectors of disease that are considered agents of bioterrorism and/or responsible for emerging and re-emerging diseases. The program overview can be downloaded here.
The JCVI GSC, contract is a new award that continues a previous initiative (Microbial Sequencing Center), awarded in 2003. The JCVI GSC aims to provide the infectious disease research community with rapid and cost-effective high-quality sequencing services for pathogenic microorganisms - including viruses, bacteria, fungi, and protozoa - as well as invertebrate vectors. In addition, the center will conduct genotyping studies of microbes and their human hosts in order to study the variation in host response, an expansion of the initial initiative. The center also offers expertise in pathogen biology with the ultimate goal to use the sequencing and genotyping data to develop new diagnostics, vaccines, and drugs. Two other such centers are at the Broad Institute and the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine. Data generated from the sequencing and genotyping projects will be released to the scientific community in accordance with the data and reagent sharing and release guidelines.
The sequencing and genotyping projects to be conducted by the three centers are selected from white paper proposals that can be submitted by members of the scientific community, the sequencing centers, or both. The white paper application is available here. You can contact us for advice about developing a white paper proposal. Additional information on the white paper process can also be found here.
All Publications that use data generated and/or are supported by the Sequencing Center at JCVI should acknowledge the sponsor as below:
This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract numbers N01-AI30071 and / or HHSN272200900007C.